Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.

NCT03530397 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03530397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03530397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 24, 2018
Completion date
November 30, 2027
Enrollment
400 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

selected advanced solid tumors